Entries by Thomas Gabrielczyk

Tasteful plant protein

Conventional meat production contributes to 15% of the global greenhouse gas emissions, high energy consumption and land use change. Belgian Paleo NV produces alternative protein from myoglobins of different species.

Living therapy: Microbial immunotherapy of Exeliom Biosciences gets a boost

Exeliom Biosciences, a French company focused on the microbiome-immunomodulation axis to develop next-generation immunotherapies, has announced the closing of its €24m (US$26m) Series A financing to advance the clinical development of its therapeutic pipeline, including several clinical trials of EXL01, a novel bacterial immunotherapy with applications in cancer and infectious diseases.

EU Regulation of Genome Editing in Plants not yet a law

A long-awaited draft regulation from the EU Commission’s DG Sante to deregulate the authorisation, risk assessment and labelling of a whole range of new genetically modified organisms (GMOs) has been published today by the College of the Commission. New Genomic Techniques (NGT) are introduced as an umbrella term for certain genetic engineering techniques that aim to modify DNA more precisely than "old" methods by targeting changes to pre-defined loci in the genome. The proposal creates two distinct pathways for NGT plants to be placed on the market. "Category 1 NGTs" are considered equivalent to conventionally bred plants and no longer require prior case-by-case risk assessment.

Biosimilars climb the alps

Generic and biosimilar manufacturer Sandoz is expanding with a new biologics production facility in Lendava, Slovenia to prepare for more demand in Europe for biosimilar products.